International Journal of Radiation Oncology * Biology * Physics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Randomized Clinical Trial of Tele-Surveillance and Remote Symptom Monitoring Compared to Standard Surveillance for HPV-Associated Oropharynx Cancer with No Evidence of Disease on Post-Treatment Imaging
The incidence of Human Papilloma Virus (HPV) associated oropharyngeal cancer has risen rapidly over the past two decades with excellent prognosis and high rates of locoregional control. Post-treatment PET/CT for oropharyngeal cancer has a very high negative predictive value. Despite the improved outcomes for HPV-associated oropharyngeal cancer and the predictive value of post-treatment PET/CT, national guidelines for post-treatment surveillance of oropharyngeal cancer do not distinguish according to HPV status. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: K. Zakeri, D. Gelblum, L. Chen, A. Kriplani, W. Wong, Z. Zhang, A. Lopez, R.J. Wong, J.R. Cracchiolo, E. Sherman, N.Y. Lee Tags: 130 Source Type: research

App-based Interactive AI Guiding Physicians in Real Time to Avoid Radiation Treatment Complications
With improved effectiveness of contemporary treatment, head and neck cancer patients have longer projected life expectancies and commonly develop late treatment adverse effects. Mountains of AI data aim at predicting outcome, few, if any, aim at preventing the foreseeing unfavorable outcome from happening. The purpose of this study was to develop an app-based interactive artificial intelligence (AI) to allow physicians to modify radiation treatment planning in real-time to avoid treatment related complications. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A.W. Chan, S.I. Goldberg, G. Steblovsky Tags: 131 Source Type: research

Detectable Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA in Non-Oropharyngeal Head and Neck Cancers
Plasma ctHPVDNA is detectable prior to treatment in ∼90% of patients with HPV-OPSCC and has shown utility in the dynamic monitoring of treatment response and detecting recurrences (4, 5, 6). Recent data has demonstrated ctHPVDNA to be detectable in patients with sinonasal and nasopharyngeal primary tumors (7). Herein, we present our early experienc e of ctHPVDNA detection in non-oropharyngeal HPV-associated head and neck cancers using an ultrasensitive multianalyte droplet polymerase chain reaction assay that tests for cell free tumor tissue modified viral (TTMV)-HPV DNA (liquid biopsies). (Source: International Journal ...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: E.W. Duffy, J. Kaczmar, W. Albergotti, A. Kejner, J.G. Newman, E.M. Graboyes, A. Tamblyn, B.S. Chera Tags: 132 Source Type: research

AI-ing Microenvironment Improves Prediction of Extracapsular Nodal Extension in Oropharyngeal Carcinoma
Deintensification for early-stage oropharyngeal carcinoma includes surgery +/- adjuvant radiation therapy without the use of concurrent chemotherapy. Pathologic findings of nodal extracapsular extension (ECE), however, obligate the use of postoperative concurrent chemotherapy in these patients. Machine learning (ML) and deep learning (DL) algorithms using clinical annotations or CT images have yielded less than optimal ECE prediction with AUCs of 0.58-0.85. We hypothesized that interplay between involved nodes and peritumoral environment plays a pivotal role in ECE determinants. (Source: International Journal of Radiation ...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R. Paul, J. Richmon, A.W. Chan Tags: 133 Source Type: research

Access to Head and Neck Cancer Specialists: A Geospatial Analysis of U.S. Travel Time
This study aims to assess geographic disparities across the United States using geospatial analysis. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: B. Goodnight, G.J. Hanna, F. Sieling, A. Fortman, D. Zheng, M. Habila, M. Cassese, S. Merchant, C.M. Black Tags: 134 Source Type: research

Geographical Disparities in the Management of Early-Stage Oropharyngeal Squamous Cell Carcinoma (OPSCC) in the United States (US)
To identify treatment modality variations for OPSCC within the US based on social determinants of health (SDOH), treatment facility characteristics, and distance to facility. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: G. Hernandez-Herrera, F.O. Olawuni, A.Q. Zhu, C.N. Abdel-Halim, C.N. Day, D.M. Routman, K.M. Van Abel Tags: 135 Source Type: research

Addressing Positive Multi-Cancer Early Detection Tests in Head and Neck Surgery: Experience with Head and Neck Work Up for High-Risk Referrals
Multi-cancer early detection (MCED) tests offer population-based screening for cancer using minimally invasive blood-based sampling and are now commercially available on a self-pay basis. Patients may be identified as at risk for head and neck cancer (HNC) based on a positive signal and predicted site of origin. Detailed information about subsite of origin is not available. There are currently no consensus guidelines available for HNC providers to direct work up or surveillance for these patients. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: C.Y. Zhao, F. Fearington, S. Romero-Brufau, E.J. Moore, D.L. Price, K.K. Tasche, L.X. Yin, E. Petrie-Smith, J.B. Kisiel, K.V. Giridhar, D.M. Routman, K.M. Van Abel Tags: 136 Source Type: research

Clinical Validation of Nuclear Factor Kappa B (p65) Among Head and Neck Cancer Patients at One Institution
This study assessed NF-kB (p65) expression and its association with various clinicopathological variables in HNC patients. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R. Osei Saahene, P. Barnes, A. Mensah, L. Derkyi-Kwarteng, E. Adankwah, E. Agbo, E.S. Yahaya, P.K. Akakpo, F. Pappoe, K. Dankwa, D. Amoako-Sakyi, S.V. Nuvor, D. Obiri-Yeboah Tags: 137 Source Type: research

Introduction of Routine Postoperative PET/CT prior to Adjuvant Head and Neck Radiation Therapy
Routine clinical practice does not include postoperative positron emission tomography (PET)/CT prior to postoperative radiation therapy (PORT) for head and neck cancer. Besides logistical challenges in obtaining postoperative PET/CT within six to eight weeks after surgery, interpreting PET/CT findings in the postoperative setting can also be difficult. However, given the potential for residual or rapidly recurrent disease, postoperative PET/CT may help identify the need for additional diagnostic evaluation or alter adjuvant therapy. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: P.T. Courtney, J. Juarez, E.Y. Liu, L.W. Chau, L. Kabarame, M.L. Steinberg, R.K. Chin, R.R. Savjani Tags: 138 Source Type: research

Phase 1 Study of the Tissue Factor –Targeting Antibody-Drug Conjugate XB002 in Patients with Advanced Solid Tumors (JEWEL-101): Design of Expansion Cohorts for Squamous Cell Carcinoma of the Head and Neck
Despite recent advancements in therapy, patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a relatively poor prognosis after chemotherapy and immune checkpoint inhibitors (ICIs), with a median survival of ∼9 months, highlighting a need for novel treatments. Tissue factor (TF) is a factor VII/VIIa receptor involved in initiating the extrinsic coagulation pathway, and its overexpression has been associated with poor prognosis in several tumor types, including SCCHN. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: S. Ulahannan, M. Johnson, M. Weiss, A. Vandross, S. Vidal-Cardenas, M. Syed, A. Tolcher Tags: 139 Source Type: research

A Phase 2 Clinical Trial of Pembrolizumab with Radiation Following Progression on anti-PD-1 Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Treatment options for patients (pts) with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who have progressed on anti-PD-1 directed therapy are limited. Some of these pts may have more limited disease (oligo) progression that may be amenable to radiation therapy (RT). RT has not been tested prospectively in this setting. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.D. Schoenfeld, Y.H. Chen, L. Gunasti, A. Droznin, J. Baginska, A. Nau, J. Weirather, I. Gomez Diaz, D.N. Margalit, R.B. Tishler, K.J. Fitzgerald, R.H. Mak, R. Uppaluri, K. Sehgal, G.J. Hanna, R.I. Haddad, J. So Tags: 140 Source Type: research

Comparative Efficacy of KEYNOTE-B10 Regimen as First-Line (1L) Therapy in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): A Network Meta-Analysis (NMA) with Aggregate-Level Matching
In KEYNOTE-B10, a phase IV, single-arm trial, the combination of pembrolizumab+carboplatin+paclitaxel (referred to as the B10 regimen) demonstrated antitumor activity with a manageable safety profile as 1L therapy for R/M HNSCC. Due to the single-arm design of KEYNOTE-B10, an NMA was conducted using methodologies to incorporate data from a disconnected trial into a connected network of randomized controlled trials (RCT) to estimate the comparative efficacy of the B10 regimen versus other interventions in 1L R/M HNSCC. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: D. Zheng, C.M. Black, A. Mojebi, S. Keeping, J.E. Park Tags: 141 Source Type: research

Proton Re-Irradiation in the Adjuvant Setting for Head and Neck Squamous Cell Carcinoma with High Risk Features
For patients with head and neck squamous cell carcinoma (HNSCC), locoregional failure and second primary tumors are common indications for adjuvant re-irradiation (re-RT). Given an absence of clear consensus on the role of adjuvant reRT, we sought to evaluate histopathologic risk factors of HNSCC patients and their resulting outcomes after adjuvant re-RT with proton therapy. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R.L. Bakst, K. Hsieh, E. Genden, K. Sindhu, D.R. Dickstein, M. Posner, W.H. Westra, D. Kirke, S. Roof, B. Culliney, M. Khan, C. Hsieh, M. Urken, R. Chai, J.T. Liu Tags: 142 Source Type: research

Can Circulating Tumor DNA be Utilized as a Marker to Guide High-Risk Head and Neck Squamous Cell Patients Treatment?
The purpose of the study was to define whether circulating tumor DNA (ctDNA) can be used as a measure to detect minimal residual disease (MRD) following surgical intervention in high-risk positive patients for head and neck squamous cell carcinoma (HNSCC). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: M.D. Orland, M. Stewart, N. Rajaram Siva, T. Kuzmanovic, N. Karasik, S.R. Campbell, J.A. Miller, N.M. Woody, N. Silver, J. Ku, J. Scharpf, E. Lamarre, B. Prendes, T. Sussman, J.L. Geiger, E. Yilmaz Tags: 143 Source Type: research

Sequential Treatment Use in Clinical Practice for U.S. Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Since the approval of pembrolizumab monotherapy in the platinum-refractory setting for R/M HNSCC in 2016 and the subsequent approval of pembrolizumab alone or in combination with chemotherapy in first-line (1L) in 2019, pembrolizumab-based therapy has become a standard of care. To better understand current real-world practice patterns, this study assessed the use of sequential systemic treatment from 1L to 2L for patients with R/M HNSCC. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: D. Zheng, C.M. Black, G.M. Hair, B. Bidadi, N. Lerman, L. Ai, A. Zion, L. Zou, W. Gao, G.J. Hanna Tags: 144 Source Type: research